Resmed Inc DRC

Research Resmed Inc DRC (RMEA) on Bullrun: valuation model: 20.0% undervalued, market cap EUR 23.06B, P/E 17.7, dividend yield 1.3%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerRMEA
ExchangeF
CountryUnited States
SectorHealthcare
IndustryMedical Instruments & Supplies
CurrencyEUR
Valuation signal20.0% undervalued
Market capEUR 23.06B
P/E17.7
Dividend yield1.3%
Financial periodQ1 2026
RevenueEUR 1.43B
Net incomeEUR 398.73M
Free cash flowEUR 514.54M
Gross margin62.2%

Valuation Snapshot

Bullrun's latest valuation model marks Resmed Inc DRC as 20.0% undervalued; latest market cap is EUR 23.06B; P/E is 17.7; dividend yield is 1.3%.

About Resmed Inc DRC

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software.

Frequently asked questions

Is Resmed Inc DRC overvalued or undervalued?

Bullrun's valuation model currently marks Resmed Inc DRC as 20.0% undervalued.

What is Resmed Inc DRC's market cap?

Resmed Inc DRC's market capitalization is EUR 23.06B.

What is Resmed Inc DRC's P/E ratio?

Resmed Inc DRC's price-to-earnings (P/E) ratio is 17.7.

Does Resmed Inc DRC pay a dividend?

Resmed Inc DRC has a dividend yield of 1.3%.